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Abstract
Background: Uterine fibroids are non-cancerous overgrowths of the smooth muscle in the uterus. As they grow, some
cause problems such as heavy menstrual bleeding, pelvic pain, discomfort during sexual intercourse, and
rarely pregnancy complications or difficulty becoming pregnant. Multiple treatment options are available. The
lack of comparative evidence demonstrating superiority of any one treatment means that choosing the best
option is sensitive to individual preferences. Women with fibroids wish to consider treatment trade-offs. Tools
known as patient decision aids (PDAs) are effective in increasing patient engagement in the decision-making
process. However, the implementation of PDAs in routine care remains challenging. Our aim is to use a multi-component
implementation strategy to implement the uterine fibroids Option Grid™ PDAs at five organizational settings in the USA.
Methods: We will conduct a randomized stepped-wedge implementation study where five sites will be randomized to
implement the uterine fibroid Option Grid PDA in practice at different time points. Implementation will be guided by the
Consolidated Framework for Implementation Research (CFIR) and Normalization Process Theory (NPT). There will be a 6month pre-implementation phase, a 2-month initiation phase where participating clinicians will receive training and be
introduced to the Option Grid PDAs (available in text, picture, or online formats), and a 6-month active implementation
phase where clinicians will be expected to use the PDAs with patients who are assigned female sex at birth, are at least
18 years of age, speak fluent English or Spanish, and have new or recurrent symptoms of uterine fibroids. We will exclude
postmenopausal patients. Our primary outcome measure is the number of eligible patients who receive the Option Grid
PDAs. We will use logistic and linear regression analyses to compare binary and continuous quantitative outcome measures
(including survey scores and Option Grid use) between the pre- and active implementation phases while adjusting for
patient and clinician characteristics.
Discussion: This study may help identify the factors that impact the implementation and sustained use of a PDA in clinic
workflow from various stakeholder perspectives while helping patients with uterine fibroids make treatment decisions that
align with their preferences.
(Continued on next page)
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Contributions to the literature
 Our paper will determine the real-world barriers and
facilitators to the sustained implementation of patient
decision aids.

 We will provide insight on various processes to identify
patients eligible to receive a patient decision aid and how
and when to provide these tools to patients to minimize the
burden on clinic workflow.

 Ultimately, we will delineate pathways that will enable clinics
to determine how their workflow needs to change in order
to achieve the sustained implementation of a patient
decision aid.

Background
Uterine fibroids, non-cancerous overgrowths of the smooth
muscle in the uterus, develop in nearly half of all women of
reproductive age [1]. Some uterine fibroids give rise to
heavy menstrual bleeding, pelvic pain, discomfort during
sexual intercourse, pregnancy complications, and/or difficulty becoming pregnant [1]. Given racial disparities in the
US prevalence of symptomatic uterine fibroids, AfricanAmerican and Latina women may be more likely to experience these issues and also may have poorer treatment
outcomes, greater economic burden, and higher incidence
of uterine fibroids in comparison to White women [2–5].
Many options are available to treat uterine fibroids
including medications, intrauterine devices (with and
without hormones), destruction of the inner layer of the
uterine wall (endometrial ablation), removal of the uterus
(hysterectomy), removal of fibroids (myomectomy), or
reducing blood supply to the uterus (uterine artery
embolization). However, insufficient evidence exists about
the comparative effectiveness of treatments for uterine fibroids [2, 6, 7]. Choosing the best treatment option for
uterine fibroids requires women to consider the unique
characteristics of each option and weigh which option
might best fit her needs and preferences.
Patient decision aids (PDAs) like Option Grid™ can help
educate patients to better navigate preference-sensitive
treatment decisions [8, 9]. Option Grids (available in text,
picture, or online formats) present evidence-based information in a tabular format, so patients can compare options

together with clinicians [10]. Across a variety of clinical
contexts, Option Grid PDAs increase patient knowledge
and shared decision making without significantly increasing
encounter duration [11, 12]. A previous version of the uterine fibroid Option Grid increased patient engagement in
the clinical conversation, improved knowledge of treatment
options, and increased satisfaction with care [13, 14].
Implementation of PDAs remains difficult across a range
of healthcare settings [15]. System and organizational barriers relate to incentives, competing priorities, and established behavior patterns [16, 17]. Despite evidence that it is
possible to implement PDAs, particularly if implementation
is supported by clinical champions, organizational strategies, and effective electronic health record (EHR) integration efforts, more work is needed to determine how best to
routinely adopt these tools in clinical practice [18, 19].
We aim to use a multi-component implementation
strategy guided by the Consolidated Framework for Implementation Research (CFIR) and the Normalization
Process Theory (NPT) to develop a tailored strategy for
each of the five participating gynecology settings to implement the uterine fibroid Option Grid PDA. We will (1)
assess each site’s organizational readiness for patient engagement, (2) use a tailored implementation strategy to incorporate the uterine fibroid Option Grid in clinical care
at each site, (3) examine the characteristics associated with
success and failure to implement and sustain Option Grid
use in practice, and (4) integrate new evidence into existing clinical practice guidelines where feasible. We will also
evaluate the impact of the implementation strategies on
clinical and other relevant outcomes for women across
socioeconomic strata who seek treatment for symptomatic
uterine fibroids. We hypothesize that providing study
settings with various formats of PDAs to help tailor the
implementation strategy to their clinic workflow will lead
to sustained use of PDAs.

Methods
Design

We will conduct a randomized stepped-wedge study
where randomization of each site to a pre-implementation
start date occurs prior to the start of the study (see Fig. 1
for details). The stepped-wedge design with a baseline
pre-implementation phase allows for within-site pre/post
comparisons. Following the pre-implementation phase,
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Fig. 1 Stepped-wedge study design and timeline

which occurs at a different time point for each site, we will
provide a brief initiation session to introduce Option Grid
PDAs and how to use them in practice. After initiation,
clinicians will be expected to use the intervention in an
“active implementation” phase. The SPIRIT checklist (see
Additional file 1) guided our protocol development [20].
Theoretical framework

The multi-component implementation strategy is guided
by the CFIR and NPT. CFIR is a pragmatic, multilevel
framework that guides the evaluation and design of implementation studies [21, 22]. It comprises five domains
(intervention characteristics, outer setting, inner setting,
characteristics of individuals, and process) and 39 related
constructs. These domains interact with one another to
influence the effectiveness of the implementation strategy.
In the context of our study, CFIR will be used at a macro
level to guide implementation by comprehensively addressing four of the five CFIR domains: intervention characteristics, inner setting, characteristics of individuals, and
process. Table 1 provides details on the CFIR domains.
In addition to CFIR’s multilevel approach, NPT will be
used at a micro level to focus on the dynamic process that
leads to the successful implementation of an innovation in
routine clinical practice. NPT is an explanatory theory
that helps evaluators understand the process by which
organizations embed interventions into their normal work
[23, 24]. NPT has four theoretical tenets: (i) coherence,
supports individual and collective consensus about an
intervention and its purpose; (ii) collective action, the
tasks allocated to the various members within the
organization to build and sustain use; (iii) cognitive participation, the relational work that influences “implementation and legitimation”; and (iv) reflexive monitoring, the
communal appraisal work that aids assessment of the
intervention [25].
Setting

The five study sites are gynecology clinics at (i) DartmouthHitchcock Medical Center in Lebanon, New Hampshire;

(ii) Barnes-Jewish Hospital in St. Louis, Missouri; (iii) Montefiore Medical Center in Bronx, New York; (iv) Brigham
and Women’s Hospital in Boston, Massachusetts; and (v)
Mayo Clinic in Rochester, Minnesota.
Participants

We will include physicians (attending or resident) who
consent to participate in our implementation study and
provide care to women with symptomatic uterine fibroids
during the project duration at participating sites.
We will include patients showing new or recurrent
symptoms of uterine fibroids (e.g., heavy menstrual bleeding, pelvic pressure or pain) who are seeking treatment
and meet all of the following inclusion criteria: (i) assigned
female sex at birth, (ii) at least 18 years of age, (iii) speak
English or Spanish, and (iv) have the ability to complete
short surveys online independent of assistance. We will
not exclude pregnant patients. We will exclude postmenopausal patients because they may have different treatment
options than those presented in the Option Grid PDA
used in this study.
Intervention

To facilitate deliberation about treatment options, the
uterine fibroid Option Grid PDA is organized in a tabular
format and is based on patients’ frequently asked questions, which were sourced by analyzing the research literature and by qualitative inquiry with stakeholders including
gynecologists and 10 women experiencing symptoms of
uterine fibroids.
The uterine fibroid tool is one of over 22 Option Grid
decision aids developed and maintained by EBSCO
Health. We helped EBSCO adapt the Option Grid for
this study by following a multi-step Community Based
Participatory Research (CBPR) approach. The tool (as of
May 2019) compares seven treatment options (watch
and wait, medicine with hormones, medicine without
hormones, uterine artery embolization, endometrial ablation, myomectomy, and hysterectomy) and consists of
answers to six frequently asked questions: (1) What does
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Table 1 Intervention characteristics that influence implementation success (according to CFIR)
Construct

Short description

I. Intervention characteristics
A. Intervention source: quality assurance.

EBSCO Systematic Literature Surveillance System (source of evidence for
DynaMed Plus product) is best in class.

B. Relative advantage: comparison opportunity

Very few clinicians have used patient decision aids designed to facilitate
shared decision making. Our evidence so far indicates that clinical teams
are positive about their utility.

C. Adaptability: the degree to which an intervention can be adapted to
local needs.

The availability of multiple formats: online and two printed versions (text
and Picture Option Grid) allows maximum adaptability to local workflow
variations. The online tool can be sent to patients ahead of visits, as well
as after visits. The printed versions allow clinicians to tailor the content to
local practice variation and to fit the tool into their style of
communication with patients of varying literacy and computer literacy
levels. We know that clinicians value the ability to add, edit, and make
notes on these tools before they give them to patients to take home. The
use of pictures maximizes the usability and accessibility of this approach
across socioeconomic strata.

D. Trialability: local test

The cost or complexity of using Option Grid is low, and so, we anticipate
low resistance to trialability by the participating clinical teams. In other
clinical contexts, we have experienced zero resistance to trialability.

E. Complexity: as the number of steps, or the number of people or
processes increases, so does the difficulty of implementation.

The Option Grid has been designed to be fast, frugal, and outwardly
simple, so that it can fit into decision discussions that will benefit from
accurate, accessible information.

F. Design quality and packaging: instills confidence in the intervention.

The EBSCO Option Grid has achieved high quality design with
professional user centered graphic design.

G. Cost: investment, supply, and opportunity costs.

Investment will be related to the time taken to learn how to integrate the
tool into the clinical workflow, a learning curve that has been observed
to take a few interactions. The project will ensure adequate supply; future
use will need to ensure online access for sustainability. We anticipate
minimal disruption on opportunity costs—clinicians typically cover the
type of information in Option Grids. The tool makes the exchange more
efficient according to our evaluations. Evidence suggests that Option Grid
decision aids do not typically increase consultation time as the content of
the tool is information clinicians already provide to patients routinely.

II. Inner setting
B. Networks and communication: The nature and quality of webs of
social networks and the nature and quality of formal and informal
communications within an organization.

Eligible patients will be identified using the site’s outpatient scheduling
system in advance of their visit. Where possible, the eligible patients will
be sent an Option Grid in advance of their appointment and will be
instructed to bring the Option Grid to their appointment.

C. Culture: Norms, values, and basic assumptions of a given organization.

We want to help implement a process where patients are engaged in
their treatment decisions “upfront” by receiving an intervention that can
facilitate a discussion with their clinician regarding their treatment
options.

D. Implementation climate: The absorptive capacity for change, shared
receptivity of involved individuals to an intervention, and the extent to
which use of that intervention will be rewarded, supported, and
expected within their organization.

We will assess implementation climate by calculating the expected use of
the intervention which is based on the volume of patients visiting each
site who have been diagnosed with symptomatic uterine fibroids.

E. Readiness for implementation: Tangible and immediate indicators of
organizational commitment to its decision to implement an intervention.

We will determine readiness for implementation from the Measuring
Organizational Readiness for patient Engagement (MORE) survey which
will be administered prior to the commencement of the preimplementation phase to 10 stakeholders at various levels of the service
delivery team (i.e., clinicians, administrators, managers).

III. Characteristics of individuals
A. Knowledge and beliefs about the intervention: Individuals’ attitudes
toward and value placed on the intervention as well as familiarity with
facts, truths, and principles related to the intervention.

ADOPT is a measure of patient attitudes to patient decision aids.
Clinicians will be asked to select one or more words that best describes
their attitudes to the potential use of patient decision aids from a pool of
ten words.

B. Self-efficacy: Individual belief in their own capabilities to execute
courses of action to achieve implementation goals.

The words selected by the participating clinicians who complete the
ADOPT measure will be indicative of their self-efficacy or the belief in
their ability to execute the course of action and achieve implementation
goals.
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Table 1 Intervention characteristics that influence implementation success (according to CFIR) (Continued)
Construct

Short description

C. Individual stage of change: Characterization of the phase an individual
is in, as he or she progresses toward skilled, enthusiastic, and sustained
use of the intervention.

We will compare collaboRATE scores (three-item patient-reported
outcome measure) before and after the initiation phase to determine
individual stage of change.

D. Individual identification with organization: A broad construct related to Ten stakeholders at various levels of the service delivery team (i.e.,
how individuals perceive the organization, and their relationship and
clinicians, administrators, managers) at each site will complete the
Measuring Organizational Readiness for patient Engagement (MORE)
degree of commitment with that organization.
survey.
E. Other personal attributes: A broad construct to include other personal
traits such as tolerance of ambiguity, intellectual ability, motivation,
values, competence, capacity, and learning style.

Personal attributes will be determined via the ADOPT survey. Clinicians
will circle up to 10 words that will be indicative of their personal traits.

IV. Process
A. Planning: The degree to which a scheme or method of behavior and
tasks for implementing an intervention are developed in advance and
the quality of those schemes or methods.

We will be visiting each site multiple times throughout the study to
provide support and assess the degree to which each site is willing to
adopt our processes.

B. Engaging: Attracting and involving appropriate individuals in the
implementation and use of the intervention through a combined
strategy of social marketing, education, role modeling, training, and other
similar activities.

Our second site visit will aim to attract and involve appropriate
individuals in the implementation and use of the intervention. In addition,
we will be providing initiation to clinicians to teach them how to use the
tools in practice. Each site will also have a “clinical champion”/site
principal investigator that will support the implementation of the
intervention. The strategy will also include feedback on study processes
from the members of the Community Advisory Board.

C. Executing: Carrying out or accomplishing the implementation
according to plan.

The primary outcome measure is the number of eligible patients who
receive the uterine fibroid Option Grid.

D. Reflecting and evaluating: Quantitative and qualitative feedback about
the progress and quality of implementation accompanied with regular
personal and team debriefing about progress and experience.

A 23-item instrument—NoMAD Normalization Process Theory (NPT)
survey—will be used to capture the perspective of professionals directly
involved in the work of implementing the intervention. We will also
conduct semi-structured interviews with a convenience sample of
clinicians and staff at each of the five clinical sites to identify, monitor,
and assess the progression and integration of the intervention and to
determine the utility of the Option Grid patient decision aid and the
barriers and facilitators to their integration in the clinic workflow.
We will also be receiving feedback at our annual site visit to determine
the process each site is using to facilitate implementation of the
intervention. The outcomes we will be measuring include the extent to
which tools are delivered, the extent to which patients are reporting use
of Option Grid in appointments, and the collection of collaboRATE scores.

it involve? (2) Will I have less bleeding and pain? (3)
Will the fibroids go away or get smaller (in size)? (4) Is
it safe to get pregnant? (5) What are the side effects?
and (6) What are the more serious risks? The uterine fibroid Option Grid is designed to be accessible to patients across socioeconomic and health literacy strata
using plain language (readability of 6th grade or less).
See Fig. 2 to view the text version of the Option Grid.
There will be two versions of the uterine fibroid Option Grid available in this trial: (i) text and (ii) text with
pictures (Picture Option Grid). The Picture Option Grid
uses the same evidence as the text version while integrating images, thus utilizing pictorial superiority to help
patients better understand and remember information
[26]. Both the text and Picture Option Grid will be available to clinicians and patients on paper pads and integrated into the EHR, leading to a website where the
clinician can select the uterine fibroid Option Grid and
choose any number of treatment options specific to the
patient to generate the comparison table. The online

version also offers the clinician a standard phrase to
document the presentation of the Option Grid to patients. It can be copied and pasted into the EHR, and the
tool can also be sent via the patient portal or by email to
the patient. The content and layout of the online Option
Grid will be maintained to match that of the text and
Picture Option Grid versions for the duration of the
project period. The different versions provide clinicians
with options, so they can choose the format that best
suits their workflow. Both versions will be available in
English and Spanish (see “Translation procedure” section
for details).
Option Grid PDAs, in any of the different formats, are
designed as catalysts for discussion between patients and
clinicians to compare options and come to agreement
about the best treatment choice.
Translation procedure

The text and Picture Option Grid used in this study will
be translated into Spanish using an adapted version of
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the Translate, Review, Adjudicate, Pretest, Document
(TRAPD) translation procedure [27, 28]. Our translation
approach will include four main stages: (i) Two suitably
qualified native speakers of the target language create independent translations of the original text; (ii) a bilingual
reviewer (who is a native speaker of the target language)
compares the original text, translation 1, and translation
2 and either selects the preferred translation or produces
a third translation that builds on the previous two; (iii)
the bilingual reviewer meets with the project team to
review and reconcile translations by consensus; (iv) the
resulting translation is tested via cognitive debrief interviews with a small sample of patients fluent in the target
language. Cognitive interview participants will each be
offered a $10 honorarium.
Outcomes and data collection
Primary outcome measure

The primary outcome measure is the number of eligible
patients who receive the uterine fibroid Option Grid
(three formats available).
Eligible patients will be identified in advance by the project team at each site through their outpatient scheduling
systems. This process will enable us to determine the total
number of patients who are eligible to participate in the
study (the denominator). To calculate the number of
patients who receive an Option Grid (numerator), we will
provide each site with a box filled with text and Picture
Option Grid paper pads. Pads will be available in every
consultation room within each sites’ obstetrics-gynecology
clinic. To use a paper-based Option Grid, the clinician will
tear it from the pad and a numbered stub will remain
where they will write their name and indicate if they are
an attending clinician or a resident (see Fig. 3 for a
mockup of the paper pad stub). The research assistant at
each site will refer to the numbered stubs to document
the number of patients who received an Option Grid on a
weekly basis. The research assistant will keep a log of the
numerator and denominator in an Excel file and will
report the data back to the Dartmouth project staff on a
weekly basis via the Qualtrics database.
For sites with EHR access to the online uterine fibroid
Option Grid, we will derive weblog data from EBSCO
Health including the date and time the tool was generated; this data will be incorporated into measurement of
the primary outcome.

Fig. 3 Paper-pad mockup to identify the number of eligible patients
receiving the uterine fibroid Option Grid in the clinic
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Secondary outcome measures

In addition to recording each site’s chosen implementation strategy and if/how it changes during the implementation and sustainability phases, we will collect
the following secondary outcome measures (as outlined in Table 2):
 Measuring Organizational Readiness for patient

Engagement (MORE). MORE is designed to measure
a healthcare organization’s willingness and ability to
effectively implement patient engagement in
healthcare [29]. The measure contains 25 items that
are each scored on a four-point Likert-type scale
(1 = avoid/not important; 4 = definitely involve/very
important) [29]. Data from the measure will be
analyzed to identify barriers and facilitators to
implementation at each site and tailor the
implementation strategy accordingly.
Each site PI will be asked to nominate 20–30 MORE
recipients within their department. Dartmouth study
staff will then email the online survey link to
nominees in the 2 months preceding the
pre-implementation phase at each site.
 Attitudes toward Decision Aids fOr PatienTs
(ADOPT). ADOPT is a measure of patient attitudes
and perceptions toward PDAs. Clinicians are asked
to select one or more words that best describe(s)
their attitudes to the potential use of PDAs from a
pool of 10 words. It can be completed by clinicians
who have, or have not, used PDAs.
ADOPT will be administered to all participating
clinicians at three time points: (i) the start of the
pre-implementation phase, (ii) the end of the active
implementation phase, and (iii) the end of the
sustainability phase. The surveys will be distributed
via email to participating clinicians using a secure
web link.
 Extent of shared decision making. Observer
OPTION-5 is a validated, observational measure. It
is a five-item scale, with each item rated from “0” to
“4” where “0” represents the absence of a shared
decision-making specific competency and “4”
represents optimal performance [30].
A research assistant employed at each site will
audio-record five clinical encounters in both the
pre- and active implementation phases for each
participating clinician that consents to
audio-recording. In each phase, we will establish a
recruitment day(s) each week where a research
assistant will approach as many eligible patients as
possible to seek consent to audio-record their visit.
This will be repeated each week until five
encounter recordings per clinician per phase are
obtained (10 per clinician in total). In the active

Scalia et al. Implementation Science

(2019) 14:88

Page 8 of 13

Table 2 Implementation sustainability outcome measures for patient outcomes
Implementation phases
Pre

Active

Sustainability

✓

✓

✓

Percentage of eligible patients receiving intervention
(primary outcome measure)

✓

✓

✓

Quality of shared decision-making process using Observer OPTION-5

✓

✓

Organizational readiness (Measuring Organizational
Readiness for patient Engagement survey)

✓

Clinician attitudes to PDAs (ADOPT: Attitudes toward
Decision Aids fOr PatienTs survey)

✓

Utility of tools and approach (clinician interviews)
Normalization Process Theory: NOMAD Toolkit (interviews)

✓

✓
✓

✓

Intervention fidelity assessment using observer checklist
Patient outcomes
Uterine Fibroid Symptom and Health-Related
Quality of Life Questionnaire (UFS-QOL)
symptom severity subscale (8-items)

✓

✓

collaboRATE (three items)

✓

✓

The Comprehensive Score for financial Toxicity (COST)—one selected item

✓

✓

Resource utilization (ambulatory and hospital visits)

✓

✓

Intended and received treatment

✓

✓

Chew health literacy measure (one item)

✓

✓

Patient demographics (email address, health insurance
status, age, race, gender, and spoken
language)

✓

✓

implementation phase, we will begin the audiorecording recruitment process described above
2 months into the phase to allow clinicians time
to get comfortable and confident with the
intervention prior to recording. We will consult
with sites to determine if we will audio-record
encounters that take place between residents and
patients. We anticipate a patient consent rate of
50 to 60% [31].
 Fidelity of intervention use. The fidelity assessment
checklist enables us to determine if an Option Grid
was used, how and when it was delivered to the
patient, whether or not the clinician made a
treatment recommendation or elicited patient
preference, and the identification of the final
treatment decision [32]. The checklist will help us
understand if clinicians are using the tools as
intended following initiation.
The checklist will be completed independently by
two Dartmouth-based project staff while listening to
the audio-recorded clinic visits.
 NoMAD Normalization Process Theory (NPT)
survey. A 23-item instrument used for capturing the
perspective of professionals who will be involved in
implementing and using Option Grid in practice
[33]. The instrument contains four sections that ask
questions on the various facets of implementing and

using the intervention such as the effect that it has
on workflow, the work and resources needed to
drive implementation, and critical appraisal of the
Option Grid.
A convenience sample of 10 stakeholders at various
levels of the service delivery team (i.e., clinicians,
medical assistants, nurses, coordinators, managerial
and reception staff) from each site will have the
opportunity to complete the NoMAD survey at two
time points: (i) at the end of the pre-implementation
phase and (ii) at the end of the sustainability phase.
Participants will be asked to provide their name
each time they complete the survey. Stakeholders
can complete the survey during a site visit, or they
will have the opportunity to complete it online after
the project team at Dartmouth sends a secure
WebLink via email.
 Utility of Option Grid PDAs and clinician approach
to implementation. Semi-structured interviews,
guided by NPT, will be conducted with clinicians to
assess the utility of the Option Grid tools and how
they implemented the intervention in practice.
A member of the project team at Dartmouth will
conduct semi-structured interviews in-person or via
phone with a convenience sample of clinicians at
each of the five clinical sites to determine the utility
of the uterine fibroid Option Grid PDA and the
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barriers and facilitators to its integration in the
clinic workflow at two time points: (i) at the end of
the active implementation phase and (ii) at the end
of the sustainability phase.
Throughout the pre- and active implementation
phases, eligible patients at each site will be invited by
clinic staff to take a survey on a tablet computer following their clinical encounter (see Additional file 2 to view
the patient survey). Clinic staff may provide the patient
with the tablet computer or refer them to a kiosk located
in the clinic that will contain the tablet. At the start of
the survey, patients will be given the opportunity to view
the study information and provide consent to participate
in the study. The survey will collect the following patient-reported outcomes, in addition to the patient’s
email address which will be used to send patients a
WebLink to the follow-up survey 3 months after their
first survey is completed. The follow-up survey can be
completed on a personal computer or mobile device. We
anticipate that approximately 30% of eligible patients will
complete the post-encounter survey. The following is a
list of patient-reported outcomes that we will be assessing:
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 collaboRATE. collaboRATE is a three-item,

patient-reported experience measure of how patients
perceive the effort that clinicians make to achieve
three core aspects of shared decision making:
informing patients, eliciting preferences, and
integrating preferences into decisions made [27, 34].
Patients answer each question on a scale of 0 to 9.
The measure is scored by using the percentage of
patients who give the highest possible score of 9 for
each item (top score) [27, 34].
 Uterine Fibroid Symptom and Health-Related
Quality of Life Questionnaire (UFS-QOL) symptom
severity subscale. We will ask patients to complete
only the symptom severity subscale portion of the
37-item UFS-QOL questionnaire. The eight-item
subscale asks patients how distressed their
symptoms have made them feel over the past
3 months [35]. Each item is scored on a Likert-type
scale from “1” (none of the time) to “5” (all of the
time) [35].
 The Comprehensive Score for financial Toxicity
(COST). COST is a patient-reported outcome
measure to assess financial toxicity in patients with
cancer [36, 37]. The measure contains 11 items.
Study stakeholders, including patient partners, felt
that the majority of the items were not applicable
for this study and wanted to minimize respondents’
burden; therefore, we opted to only use one item.
The question reads: “I worry about the financial
problems I will have in the future as a result of my



illness or treatment”, and the response scale is from
“0” (not at all) to “4” (very much).
Chew Health Literacy Measure. Three-item validated
measure of health literacy. The items are the
following: How confident are you filling out medical
forms by yourself? How often do you have someone
(like a family member, friend, hospital/clinic worker,
or caregiver) help you read hospital materials? How
often do you have problems learning about your
medical condition because of difficulty understanding
written information? Patients who circle “extremely”
or “quite a bit” on the Likert-type scale are considered
to have high health literacy [38].
Resource utilization (ambulatory and hospital). The
follow-up survey will query eligible patients to
self-report the number of outpatients (or visit to
primary care clinician), inpatient, or emergency
visits during the 3-month follow-up period.
Treatment choice. Patients will identify their
intended treatment choice in the post-encounter
survey. We will also ask patients in the 3-month
follow-up survey whether they have seen another
clinician about another treatment, whether an
Option Grid tool was used in that encounter, and to
identify the final treatment option they selected, or
will select if they proceed with scheduling the
treatment intervention.
Patient demographics. We will collect the patient’s
email address, health insurance status, age, race,
gender, and spoken language via the survey they
complete on the tablet computer post-encounter.

Procedure

The implementation procedure was guided by CFIR’s
inner setting and its related constructs (see Additional file 3
for details).
Clinician consent

Dartmouth project staff met with clinicians at each site in
January and February 2019 to introduce the project. Co-investigators and stakeholder partners at each site will
help identify clinicians who are eligible to participate in
the study prior to the start of their pre-implementation
phase and ahead of their second site visit. Prior to the
second site visit, the principal investigators at each site will
receive an information sheet describing the aims and
methodology of the study via email. They will disseminate
the information sheets to eligible clinicians. Eligible clinicians who wish to participate can provide their written
consent in-person during the project staff’s second site
visit, email their consent forms to the project staff at their
earliest convenience, or return them to project staff at
each site. Clinicians can opt-in on the consent form to
have a sample of 10 of their clinical encounters audio-
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recorded over the course of project. We will determine
before the site visits if residents are eligible to have a sample of their encounters audio-recorded. Clinicians who
opt to participate will be sent a secure web link to a survey
via email, so they can provide their age, gender, and years
of experience post-fellowship (or year(s) of residency).
Randomization

The five participating sites were randomized by the project staff’s statistician, who was blinded to the identity of
the sites, using R statistical software.
Pre-implementation phase

Prior to the start of the pre-implementation phase, stakeholders will complete the MORE survey. At the start of the
pre-implementation phase, participating clinicians at each
site will complete the ADOPT survey to indicate their attitude toward PDAs. We will audio-record five clinical
encounters for each consenting participating clinician, and
at the end of the study phase, we will conduct interviews
with a convenience sample of clinicians and staff at each
site to inform their completion of the NoMAD survey (see
data collection section for details).
The Option Grid will not be used during the pre-implementation phase; however, patients will still complete
the survey (see patient outcomes section for details) following their clinical encounters to provide baseline data
for each site.
Initiation on how to practice shared decision making using
the Option Grid tools

The study interventions will be carefully described to
participating clinicians at each site during an initiation
session that will take place within a 2-month phase
between the pre- and active implementation periods. The
principal investigators (GE and M-AD) will introduce the
concept of shared decision making and Option Grid PDAs
to stakeholders at each site using webinars, video-conferences, and face-to-face coaching based on the “three talk
model of shared decision making” [39, 40]. The format of
the initiation will be adapted for each site, based on
MORE survey results. Each site will determine which Option Grid PDA formats to implement (text, picture, and
online versions). During the initiation phase, the Dartmouth project team will also provide each site with its
clinic-level collaboRATE top score percentage from the
pre-implementation phase as insight into baseline patientrated shared decision-making performance.
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section above. Each site will keep a weekly record of the
number of eligible patients who received the Option
Grid (primary outcome).
As in the pre-implementation phase, patients will
be asked to complete a survey (1) immediately following the clinical encounter and (2) 3 months after the
clinical encounter.
Two months into the active implementation phase,
research assistants at each site will begin audio-recording clinical encounters until each participating clinician
(who consents to audio-recording) has had five of their
encounters recorded. The audio-recordings will be sent
to the project team at Dartmouth using a secure and
HIPAA-compliant platform (Dartmouth Sharepoint).
Two independent raters will assess (using the Observer
Option-5 measure and fidelity checklist) the extent to
which clinicians involve patients in the decision-making
process using Option Grid tools. At the end of the active implementation phase, clinicians will complete the
ADOPT survey, and we will conduct semi-structured
interviews, guided by CFIR and NPT, with a convenience sample of participating clinicians to determine the
tools’ utility, and the barriers and facilitators of their
use in practice.
Sustainability phase

Prior to the sustainability phase, we will provide text and
Picture Option Grid PDAs to each site. Project staff will
limit communication with clinical sites throughout this
phase to prevent unintended influence on continued
PDA use. At the end of the sustainability phase, we will
measure the number of eligible patients who receive the
uterine fibroid Option Grid and clinician attitudes. We
will also inquire about if and how study teams plan to
use the text or Picture Option Grids after our study has
ended, and we will assess the utility of the intervention
from varied stakeholder perspectives at each site.
With the goal of offering guideline developers expertise
on how to integrate shared decision-making processes
into their documentation, we will contact organizations
responsible for clinical practice guidelines regarding management of uterine fibroids. We will share the Option
Grid and the evidence summaries created for the development of the existing tools, as well as indicating the new
PCORI-generated evidence that we have considered in
developing the PDA [41]. These steps will take place over
the duration of the implementation study.

Active implementation phase

Statistical analysis
Power calculation

During each site’s active implementation phase, the uterine fibroid Option Grid PDA will be incorporated into
the routine clinic workflow according to a tailored implementation strategy, as described in the “intervention”

The primary analysis has an expected sample size of
2600 patients across 30 to 40 clinicians (an estimated 87
patients per clinician [n = 30]) at each of the five sites.
Because the intervention varies within clinician and our
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statistical models include clinician random and site-fixed
effects, the relevant clustering variable is clinicianproject week. With 40 project weeks and at least 30 clinicians, clustering is likely to have minimal impact on
the results. Therefore, for a binary dependent variable
(e.g., whether the uterine fibroid Option Grid is used or
whether the patient gives a top collaboRATE score) with
a baseline proportion of 0.5, a symmetric two-sided 95%
confidence interval of width of at least 0.048 will have
an 80% coverage probability of containing the true effect
of the intervention, i.e., attaining a confidence margin of
0.048. In the context of shared decision making, such a
margin is small and below typical levels of precision obtained from randomized studies.
Data analysis

Patient-level data will be clustered by site and clinician.
Patients will be assigned to a single phase based on the
date of their first encounter with a clinician at the site
during the project period. Instances in which a patient
has a repeated visit in the pre- and active implementation periods will be recorded to enable sensitivity analyses accounting for repeated observations.
Regression analyses will compare quantitative outcome
measures (including survey scores and Option Grid use)
between the pre- and active implementation phases
while adjusting for patient and clinician characteristics.
The extent to which clinicians involve patients in decision-making for each recorded encounter will be
assessed by analyzing the Observer OPTION-5 and Option Grid fidelity checklist data from each phase of the
study. We will conduct a framework analysis, guided by
NPT, of the clinician interview transcripts to determine
the barriers and facilitators of Option Grid implementation. Completion of the NoMAD Normalization Process
Theory survey, based on interviews with site stakeholders, will enable us to make across-site assessments
of implementation sustainability.
Data management and storage

All patient and clinician survey data will be stored in
the Dartmouth Qualtrics database, a HIPAA-compliant
web-based data management system. We will assign a
unique study identification number to patient and clinician participants. All audio-recordings of clinical encounters and semi-structured interviews will be loaded
by site-based project staff into Dartmouth’s HIPAAcompliant SharePoint system. Each recording will be
labeled with a unique identification number. For statistical analysis, data will be downloaded from Qualtrics
and stored on an encrypted hard drive owned by Dartmouth College. Stata software will be used for statistical analysis.
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Discussion
Our study maps the various routes to implementing
PDAs in clinic workflow by studying timing and mode
of delivery, available formats (online, text, and picture),
and tailored implementation strategies determined by
each organization’s readiness for patient engagement.
This study also explores ways to overcome the barriers
and facilitators to implementation from various stakeholder perspectives, guided by CFIR and NPT. Further,
we will assess the impact of the implementation strategy
on clinical and other relevant outcomes for women
across socioeconomic strata. Our study aims to improve
healthcare delivery for women with symptomatic uterine
fibroids by empowering them, through the use of a PDA,
to be more active in the decision-making process.
We anticipate that healthcare organizations who
wish to use PDAs will use our findings to inform
their implementation strategy. This work will help
stakeholders identify how and when to best deliver
these tools to patients. This study can help identify
barriers to implementation of PDAs, enabling providers to proactively address such barriers. Reflecting
on their workflow will enable site staff to understand
how to potentially change their system to better identify
eligible patients and deliver the tool in a minimally
disruptive fashion. Findings can encourage clinicians in
gynecology departments to use PDAs with their patients
given the positive effects of these tools on communication
and outcomes.
The use of two validated frameworks to guide each
site’s implementation strategy is a strength of our study
[21–24]. In addition, we are assessing implementation
from various stakeholder perspectives using both qualitative (interviews) and quantitative (survey) methods.
We are providing each site with flexibility, so they can
determine how best to implement Option Grid based
on their clinic workflow patterns and organizational
readiness for this type of approach. A potential limitation is that the outer setting domain of the CFIR framework is not addressed as extensively as the other
domains (see Table 1). However, the integration of new
evidence into existing clinical practice guidelines (component 4 of our strategy) addresses, to an extent, the
external policy and incentives construct embedded in
the CFIR outer setting domain. A further challenge will
be determining the best method to ensure that all eligible patients receive the uterine fibroid Option Grid.
However, we are collaborating with principal investigators, who are all practicing clinicians, at each site to
overcome this challenge.
We will take an active approach to disseminating study
findings by engaging key stakeholders—patients, caregivers, community members, health professionals, and
policy makers—in identifying the message and the means

Scalia et al. Implementation Science

(2019) 14:88

of communication to appropriate audiences [42]. Potential
dissemination strategies may include the use of social
media, lay press, and academic.
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